$GALT News
Last published 6d ago
- 6d agoGALTGalectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026GlobeNewswireGalectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters
- 2mo agoGALTGalectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireNORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present
- 2mo agoGALTGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business UpdateGlobeNewswireNORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 3mo agoGALTGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance SheetGlobeNewswireChairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS,
- 4mo agoGALTGalectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal HypertensionGlobeNewswireGalectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026 and is actively
- 5mo agoGALTGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH CirrhosisGlobeNewswireData from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis balance, as
- 6mo agoGALTGalectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business UpdateGlobeNewswireNORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 6mo agoGALTGalectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of HepatologyGlobeNewswireNORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and
- 7mo agoGALTGalectin Therapeutics Reports 2025 Financial Results and Provides Business UpdateGlobeNewswireNORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 8mo agoGALTGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ETGlobeNewswireNORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today
- 10mo agoGALTGalectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027GlobeNewswireNORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today
- 12mo agoGALTGalectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business UpdateGlobeNewswireNORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 1y agoGALTGalectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual MeetingGlobeNewswireNew biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with
- 1y agoGALTGalectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor ConferenceGlobeNewswireNORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will
- 1y agoGALTGalectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025GlobeNewswireNORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today
- 1y agoGALTGalectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireNORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will
- 1y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business UpdateGlobeNewswireNORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 1y agoONCYGALTPRPHCGON+1Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is GoingPR NewswireUSA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report...
- 1y agoGALTGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal HypertensionGlobeNewswireNORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today
- 1y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business UpdateGlobeNewswireNORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 1y agoGALTGalectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 CongressGlobeNewswireData presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol
- 1y agoGALTGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 CongressGlobeNewswireNORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today
- 1y agoGALTGalectin Therapeutics Reports 2024 Financial Results and Provides Business UpdateGlobeNewswireNORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 1y agoGALTGalectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE TrialGlobeNewswireAdditional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo in per-protocol patients (completers) enrolled in
- 1y agoGALTGalectin Therapeutics to Present at the 2025 MASH-TAG ConferenceGlobeNewswireNORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE
- 1y agoGALTGalectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASHGlobeNewswireIn the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placeboWhile there was a
- 1y agoGALTGalectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingGlobeNewswirePatient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review system can be
- 1y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business UpdateGlobeNewswireNAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin
- 2y agoGALTGalectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingGlobeNewswireNORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase
- 2y agoGALTGalectin Therapeutics to Participate in the H.C. Wainwright MASH ConferenceGlobeNewswireNORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer
- 2y agoGALTGalectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireNORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer
- 2y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business UpdateGlobeNewswireNAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target
- 2y agoGALTGalectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical OfficerGlobeNewswireNORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D.,
- 2y agoGALTGalectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 CongressGlobeNewswireNORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and
- 2y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business UpdateGlobeNewswireFifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated
- 2y agoGALTGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect ConferenceGlobeNewswireNORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and
- 2y agoGALTGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisGlobeNewswireData and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver
- 2y agoGALTGalectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateGlobeNewswireNORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 2y agoGALTGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical DevelopmentGlobeNewswireNORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D.
- 2y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateGlobeNewswireNORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 3y agoGALTGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDGlobeNewswirePharmacokinetics and safety of belapectin in patients with hepatic insufficiencyLack of impact of belapectin on cardiac repolarization (QT interval)Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new
- 3y agoGALTGalectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023GlobeNewswireNORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the
- 3y agoGALTGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsGlobeNewswireNORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been
- 3y agoGALTGalectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver CirrhosisGlobeNewswireNORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and
- 3y agoGALTGalectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023GlobeNewswireNORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the
- 3y agoGALTGalectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023GlobeNewswireNORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the
- 3y agoGALTGalectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023GlobeNewswireNORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9th
- 3y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business UpdateGlobeNewswireNORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 3y agoGALTGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business UpdateGlobeNewswireNORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business
- 3y agoGALTGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023GlobeNewswireNORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the